STTK · Shattuck Labs, Inc. · Executive Compensation
$4.62
+0.13 (+2.90%)
At close · Nov 6
Return incl. dividend (before tax)
Q3 2023 earnings call transcript
Market Cap
$470.51M
Shares
101.84M
Volume · Nov 6
1.15M
Avg daily vol (3M)
1.14M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $1,532,763 |
| Andrew Neill | Chief Financial Officer | $883,433 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $3,216,407 |
| Andrew Neill | Chief Financial Officer | $2,052,586 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $1,034,408 |
| Andrew Neill | Chief Financial Officer | $911,757 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $1,465,211 |
| Abhinav Shukla | Chief Technical Officer | $1,199,321 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $744,451 |
| Casi DeYoung | Chief Business Officer | $523,482 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Taylor Schreiber | M.D., Ph.D. Chief Executive Officer | $2,095,466 |
| Josiah Hornblower | Chairman Former CEO and Executive Chairman | $1,459,766 |
| Casi DeYoung | Chief Business Officer | $1,213,833 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Josiah Hornblower | Chairman Former CEO and Executive Chairman | $384,368 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Helen M. Boudreau | Class III Director Nominee | Appointed | 2026-06-02 |
| Clay Siegall, Ph.D. | Class III Director Nominee | Appointed | 2026-06-02 |
| Taylor Schreiber, M.D., Ph.D. | Class III Director Nominee | Appointed | 2026-06-02 |
| Mona Ashiya | Class I director | Appointed | 2025-08-26 |
| Daniel Baker | Class I director | Appointed | 2025-08-26 |
| Kate Sasser | Class II director | Resigned | 2025-08-26 |
| Carrie Brownstein | Class I director | Resigned | 2025-08-26 |
| Michael Lee | Class I director | Resigned | 2025-08-26 |
| Tyler Brous | Class I director | Resigned | 2025-08-26 |
| Dr. Clay Siegall | Class III director | Appointed | 2024-03-04 |
| Dr. Kate Sasser | Class II director | Appointed | 2024-03-04 |
Leadership
- Taylor Schreiber CEO, Board Member
- George Golumbeski Chairman
- Andrew Neill CFO
- Stephen Stout General Counsel
- Clay Siegall Board Member
- Clay Siegall, Ph.D. Board Member
- Daniel Baker Board Member
- Dr. Clay Siegall Board Member
- Dr. Kate Sasser Board Member
- Helen M. Boudreau Board Member
- Mona Ashiya Board Member
- Neil Gibson Board Member
- Taylor Schreiber, M.D., Ph.D. Board Member
Key facts
CIK
1680367
CUSIP
82024L103
13F (30d)
41 filings
29 filers
Visit website
Investor relations